David Shaw’s United Therapeutics UTHR Stock Holding History

David Shaw’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-20,000	Closed	-$11.9M	–	5250
2026 Q1	$11.9M	Buy	+20,000	New	+$9.96M	0.01%	1505
2020 Q1	–	Sell	-44,100	Closed	-$3.88M	–	4285
2019 Q4	$3.88M	Sell	44,100 -9,200	-17%	-$810K	﹤0.01%	1931
2019 Q3	$4.25M	Hold	53,300	–	–	0.01%	1770
2019 Q2	$4.16M	Buy	+53,300	New	+$4.98M	0.01%	1713
2017 Q1	–	Sell	-20,400	Closed	-$2.93M	–	3625
2016 Q4	$2.93M	Hold	20,400	–	–	0.01%	1724
2016 Q3	$2.41M	Hold	20,400	–	–	﹤0.01%	1785
2016 Q2	$2.16M	Buy	20,400 +10,900	+115%	+$1.22M	﹤0.01%	1886
2016 Q1	$1.06M	Hold	9,500	–	–	﹤0.01%	2317
2015 Q4	$1.49M	Hold	9,500	–	–	﹤0.01%	2359
2015 Q3	$1.25M	Hold	9,500	–	–	﹤0.01%	2449
2015 Q2	$1.65M	Hold	9,500	–	–	﹤0.01%	2332
2015 Q1	$1.64M	Buy	+9,500	New	+$1.45M	﹤0.01%	2173
2014 Q2	–	Sell	-37,400	Closed	-$3.52M	–	4548
2014 Q1	$3.52M	Hold	37,400	–	–	0.01%	1853
2013 Q4	$4.23M	Buy	37,400 +17,400	+87%	+$1.57M	0.01%	1835
2013 Q3	$1.58M	Buy	+20,000	New	+$1.46M	﹤0.01%	2635

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

David Shaw's UTHR Position: Q2 2026 in Review

David Shaw sold out of United Therapeutics (UTHR) in Q2 2026, closing a stake of 99,106 shares — an estimated $58.8M sold.

David Shaw first reported a position in UTHR in Q4 2013 and held it in 48 quarters. The position peaked at $150M in Q4 2025. 874 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

David Shaw reported no remaining United Therapeutics position as of Q2 2026 after selling out during the quarter.
David Shaw sold 99,106 United Therapeutics shares in Q2 2026, an estimated $58.8M.
David Shaw first reported a position in United Therapeutics in Q4 2013 and held it in 48 quarters.
David Shaw's United Therapeutics position peaked at $150M in Q4 2025.
874 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.